Next Science Ltd
ASX:NXS

Watchlist Manager
Next Science Ltd Logo
Next Science Ltd
ASX:NXS
Watchlist
Price: 0.135 AUD -5.26% Market Closed
Market Cap: 39.4m AUD
Have any thoughts about
Next Science Ltd?
Write Note

Next Science Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Next Science Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Next Science Ltd
ASX:NXS
Current Portion of Long-Term Debt
$274.8k
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanosonics Ltd
ASX:NAN
Current Portion of Long-Term Debt
AU$3.1m
CAGR 3-Years
29%
CAGR 5-Years
48%
CAGR 10-Years
N/A
Polynovo Ltd
ASX:PNV
Current Portion of Long-Term Debt
AU$1.7m
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SDI Ltd
ASX:SDI
Current Portion of Long-Term Debt
AU$657k
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
-18%
Anteris Technologies Ltd
ASX:AVR
Current Portion of Long-Term Debt
AU$978k
CAGR 3-Years
-31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ansell Ltd
ASX:ANN
Current Portion of Long-Term Debt
$77.5m
CAGR 3-Years
55%
CAGR 5-Years
31%
CAGR 10-Years
18%
No Stocks Found

Next Science Ltd
Glance View

Market Cap
39.4m AUD
Industry
Health Care

Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. The company is headquartered in Chatswood, New South Wales. The company went IPO on 2019-04-18. The firm's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The firm's product includes XPERIENCE, SURGX, BACTISURE and BLASTX. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SURGX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel. The BLASTX is an antimicrobial wound gel.

NXS Intrinsic Value
1.454 AUD
Undervaluation 91%
Intrinsic Value
Price

See Also

What is Next Science Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
274.8k USD

Based on the financial report for Dec 31, 2023, Next Science Ltd's Current Portion of Long-Term Debt amounts to 274.8k USD.

What is Next Science Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
17%

Over the last year, the Current Portion of Long-Term Debt growth was 7%. The average annual Current Portion of Long-Term Debt growth rates for Next Science Ltd have been 17% over the past three years .

Back to Top